TA-NIC

DB05445InvestigationalProtein Based Therapies

TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. It is designed to raise anti-nicotine antibodies which bind to nicotine molecules...

Mechanism: Reduces nicotine entry into the brain and thus decreases activation of neural reward pathways associated with addiction to smoking.
Curator reviewed
Primary indication: Investigated for use/treatment in tobacco dependence.Curator reviewed
Formula / weight: C₂₆H₄₅NO₇S · 515.703 Da

What you can answer from here — as of April 02, 2025

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which companies are running trials of TA-NIC, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account